Evotec AG EVO
- Market cap
- $539.9M
- P/E
- 0.0×
Follow EVO
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.64 | 3.63 | 7.37 | 10.13 | 10.11 | 17.07 | 7.80 | 7.94 | 2.85 | 2.84 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 3.89 | 13.21 | 13.13 | 14.88 | 18.58 | 26.57 | 23.63 | 13.49 | 11.67 | 4.80 |
High Price
|
|||
| 1,238 | 2,178 | 2,617 | 3,030 | 3,572 | 4,198 | 4,952 | 5,061 | 4,827 | 4,553 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 182 | 291 | 443 | 500 | 572 | 731 | 792 | 846 | 862 | 892 |
Revenue
|
|||
| 35.59% | 32.05% | 29.84% | 29.77% | 25.10% | 24.52% | 23.16% | 22.40% | 14.41% | 14.49% |
Gross Margin
|
|||
| 36 | 30 | 85 | 63 | 29 | 280 | (162) | (87) | (210) | (98) |
EBT
|
|||
| 20.03% | 10.22% | 19.18% | 12.67% | 5.15% | 38.34% | (20.49%) | (10.31%) | (24.34%) | (11.01%) |
EBT Margin
|
|||
| 30 | 27 | 99 | 42 | 7 | 255 | (185) | (91) | (212) | (117) |
Net Income
|
|||
| 14 | 25 | 37 | 56 | 64 | 83 | 88 | 101 | 110 | 113 |
Depreciation
|
|||
| 0.69 | 1.00 | 1.50 | 1.67 | 1.86 | 2.20 | 2.24 | 2.39 | 2.43 | 2.51 |
Revenue/Sh
|
|||
| 0.11 | 0.10 | 0.34 | 0.14 | 0.02 | 0.76 | (0.52) | (0.26) | (0.60) | (0.33) |
Earnings/Sh
|
|||
| 0.28 | 0.04 | 0.63 | 0.16 | 0.17 | 0.43 | 0.61 | 0.11 | 0.06 | (0.03) |
Cash Flow/Sh
|
|||
| (0.04) | (0.07) | (0.11) | (0.12) | (0.37) | (0.42) | (0.54) | (0.66) | (0.40) | (0.26) |
Capex/Sh
|
|||
| 0.24 | (0.02) | 0.51 | 0.04 | (0.20) | 0.01 | 0.06 | (0.55) | (0.34) | (0.29) |
Free CF/Sh
|
|||
| 0.89 | 1.29 | 1.70 | 1.78 | 2.69 | 4.90 | 3.54 | 3.43 | 2.91 | 2.59 |
Book Value/Sh
|
|||
| 265 | 290 | 295 | 299 | 308 | 333 | 353 | 354 | 355 | 355 |
Shares
|
|||
| 35.39 | 91.00 | 30.41 | 92.98 | 1,048.57 | 30.94 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 5.93 | 8.16 | 6.63 | 7.70 | 9.86 | 10.81 | 3.64 | 4.90 | 1.71 | 1.23 |
PS Ratio
|
|||
| 4.56 | 6.33 | 5.85 | 7.20 | 6.83 | 4.85 | 2.30 | 3.25 | 1.43 | 1.19 |
PB Ratio
|
|||
| 5.33 | 8.54 | 6.53 | 7.98 | 9.85 | 10.23 | 3.34 | 4.28 | 1.90 | 1.19 |
EV/Sales
|
|||
| 15.29 | (355.12) | 19.17 | 363.59 | (89.05) | 2,795.22 | 121.73 | (11.96) | (13.52) | (10.25) |
EV/FCF
|
|||
| 75 | 12 | 185 | 47 | 51 | 145 | 214 | 39 | 20 | (10) |
Op' Cash Flow
|
|||
| (11) | (19) | (33) | (36) | (113) | (141) | (191) | (233) | (141) | (93) |
Capex
|
|||
| 63 | (7) | 152 | 12 | (62) | 4 | 23 | (194) | (121) | (104) |
FCF
|
|||
| 106 | (74) | 63 | 325 | 514 | 919 | 775 | 475 | 365 | 447 |
Working Cap'
|
|||
| 32 | 214 | 133 | 503 | 545 | 590 | 518 | 516 | 425 | 508 |
Total Debt
|
|||
| (108) | 111 | (44) | 144 | (5) | (426) | (239) | (137) | (4) | (31) |
Net Debt
|
|||
| 237 | 375 | 502 | 534 | 826 | 1,630 | 1,251 | 1,212 | 1,031 | 921 |
Sh' Equity
|
|||
| 8.59% | 4.80% | 11.94% | 3.82% | 0.48% | 11.82% | (7.37%) | (3.77%) | (9.41%) | (5.84%) |
ROA
|
|||
| 16.84% | 5.45% | 12.48% | 6.46% | 4.22% | 2.52% | 1.36% | (2.99%) | (9.39%) | (4.47%) |
ROIC
|
|||
| 13.71% | 8.96% | 22.68% | 8.23% | 1.05% | 20.77% | (12.85%) | (7.37%) | (18.92%) | (12.00%) |
ROE
|
|||
Evotec AG peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| EOLS Evolus, Inc. | $519.2M | 0.0× | Compare |
| KMDA Kamada Ltd. | $509.4M | 22.9× | Compare |
| TKNO Alpha Teknova, Inc. | $498.8M | 0.0× | Compare |
| TLRY Tilray Brands, Inc. | $603.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AQST Aquestive Therapeutics, Inc. | $605.0M | 0.0× | Compare |
| IRWD Ironwood Pharmaceuticals, Inc. | $692.4M | 5.2× | Compare |
| CGC Canopy Growth Corporation | $397.7M | 0.0× | Compare |
| COLL Collegium Pharmaceutical, Inc. | $737.1M | 14.7× | Compare |
Evotec AG (EVO) key facts
- Evotec AG (EVO) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
- Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was EUR 892.0 million, up 3.43% from fiscal 2024.
- Evotec AG reported a net loss of EUR 117.1 million, or a loss of EUR 0.33 per share, for fiscal 2025.
- As of September 25, 2026, EVO traded at $1.56, a market capitalization of $539.9 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.6× sales.
- Return on equity was −12.0% and debt-to-equity 0.72.
Evotec AG (EVO) Latest News
9 Sep
Evotec Biologics advances U.S. Department of War antibodies against Orthopoxvirus into Phase 1 clinical studies. Government-backed move of orthopoxvirus antibodies into Phase 1 trials signals major pipeline progress and contract potential for Evotec.
2 Sep
Evotec and Plectonic enter research collaboration to develop new T-cell-engaging approaches targeting solid tumors. Exploratory oncology collaboration may modestly advance Evotec pipeline without immediate revenue effects.
7 Aug
Evotec AG partners with Odyssey on AI-enabled R&D collaboration. AI collaboration represents strategic R&D move with moderate potential to influence Evotec innovation and positioning.
6 Aug
Evotec AG enters AI-enabled R&D collaboration with Odyssey Therapeutics targeting autoimmune and inflammatory diseases. New partnership adds AI-driven research capacity in core therapeutic areas but constitutes a standard industry collaboration without disclosed financial scale or immediate product impact.
3 Aug
Niagen Bioscience selected Evotec to advance preclinical development of NB4168. New preclinical contract adds modest revenue potential and pipeline activity for Evotec.
14 Jul
Evotec SE reported Q2 2026 revenue declines while outlining strategic actions to counter operational pressures and support long-term positioning. Revenue declines directly affect near-term financial results and may pressure investor views on Evotec's execution.
Evotec AG (EVO) released Q2 earnings call highlights covering financial results, pipeline updates and operational outlook. Q2 earnings highlights deliver updated financial metrics and pipeline status that moderately influence near-term valuation and sentiment.
13 Jul
Evotec AG announced preliminary second quarter and first half 2026 results and updated its full-year 2026 outlook. Preliminary results with outlook revision directly shape investor views and valuation.
30 Jun
Just - Evotec Biologics launches J.TRAIN platform to provide turnkey continuous manufacturing solutions for biologics. New platform launch may moderately strengthen Evotec biologics manufacturing capabilities and positioning.
2 Jun
Evotec AG appoints Rui Wang as Head of Global In Silico and AI. AI leadership hire may modestly boost Evotec computational drug discovery efforts.
13 May
Evotec nominates first preclinical development candidate from its alliance with Almirall. Nominating first preclinical candidate from Almirall alliance advances key partnership and pipeline progress with moderate impact on future performance.
12 May
Evotec SE successfully placed €116.1 million convertible bonds. €116.1 million convertible bond placement provides significant non-dilutive funding to support strategic initiatives and enhance financial position.
6 May
Evotec AG released Q1 earnings call highlights, detailing financial performance, revenue growth, pipeline progress, and strategic partnerships. Q1 earnings call highlights provide updates on financials and operations with moderately noticeable influence on performance and sentiment.
5 May
Evotec AG's CFO transition sparks investor attention and prompts a fresh valuation review of the stock. CFO change influences market sentiment and valuation scrutiny but does not fundamentally alter operations or strategy.
4 May
Evotec nominates first preclinical development candidate from dermatology collaboration with Almirall. Advances Evotec's drug discovery pipeline and partnership validation with moderate potential to influence innovation and revenue prospects.
30 Apr
Evotec AG secures grants to advance its tuberculosis treatment programs. Grants provide non-dilutive funding to progress TB pipeline, moderately boosting innovation and investor sentiment.
24 Apr
Evotec AG announces transition of its Chief Financial Officer, with the current CFO stepping down and a successor appointed. CFO transition affects financial leadership and strategy, potentially influencing investor confidence and operations moderately.
15 Apr
Evotec AG appoints Dr. Ingrid Müller as Chief Operating Officer. Appointment of a new COO impacts operational efficiency and strategic execution in a key biotech firm.
14 Apr
Evotec AG (EVO) attracts investors with its innovative drug discovery platform, extensive partnerships with major pharma firms like Bayer and Bristol Myers Squibb, diversified revenue streams, strong cash position, undervalued shares relative to peers, and promising clinical pipeline advancements. Highlights major strategic partnerships and pipeline progress poised to significantly boost revenue and market positioning.
8 Apr
Evotec AG (EVO) released the transcript of its Q3 2025 earnings call, detailing financial results, operational updates, and forward-looking guidance. Quarterly earnings calls disclose financial performance, strategic initiatives, and outlook that significantly sway investor sentiment and stock trajectory.
Evotec SE's Q4 2025 earnings call highlights strategic gains amid revenue challenges. Earnings highlights show strategic advances balancing revenue shortfalls, moderately influencing financial performance and market sentiment.
Evotec AG reported Q4 revenue of €194.1 million, up 7% year-over-year, with adjusted EBITDA of €19.4 million. Full-year revenue hit €751.6 million amid strategic shifts. Company narrowed 2024 revenue guidance to €740-780 million, lowered EBITDA outlook to €70-90 million due to cost discipline and pipeline investments. Highlighted key partnerships with Sanofi, Bristol Myers Squibb, and progress in EVT 201 for Alzheimer's. Q4 revenue growth and narrowed 2024 guidance indicate moderate financial stability but tempered by lowered EBITDA expectations amid investments.
1 Apr
Evotec AG appoints Dr. Ashiq H. Khan as Chief Commercial Officer to lead global commercial strategy and drive business growth. Appointing a seasoned Chief Commercial Officer bolsters leadership in commercialization and revenue generation.
23 Mar
Evotec Biologics enters project agreement with BARDA to optimize biomanufacturing of antibodies against Ebola and related viruses. BARDA partnership validates Evotec Biologics' manufacturing expertise and likely secures government funding for strategic viral antibody development.
19 Mar
Bristol Myers Squibb begins human testing of a novel protein degradation cancer drug developed with Evotec AG. Human trials milestone in BMS partnership validates Evotec's degradation platform and unlocks potential milestone payments.
Evotec AG received a $10 million milestone payment from Bristol Myers Squibb for initiating a clinical study in their protein degradation collaboration. $10M milestone from BMS for clinical study initiation signals partnership progress, providing non-dilutive funding and validating Evotec's protein degradation technology.
15 Mar
Evotec AG unveils 'Horizon' plan targeting EUR 75M in savings and guiding 2026 EBITDA to EUR 0-40M. Horizon plan delivers major cost savings of EUR 75M and positive 2026 EBITDA guidance, poised to significantly reshape Evotec's financial trajectory and investor sentiment.
10 Mar
Solvonis Therapeutics CEO details SVN-114's potential as a treatment for PTSD, emphasizing substantial market opportunity in an underserved area. CEO spotlight on SVN-114's PTSD potential moderately boosts Evotec's pipeline prospects and investor interest.
18 Jan
Evotec AG (EVO) is highlighted as a potential investment opportunity due to its debt-free status and position as a penny stock. The company is involved in drug discovery and development, which may attract investors looking for growth in the biotech sector. Analysts suggest that Evotec's innovative approaches and partnerships could enhance its market performance, making it a noteworthy option for investors seeking low-risk, high-reward stocks. Evotec's innovative strategies and partnerships may moderately influence its financial performance and market positioning.
11 Jan
Evotec AG (EVO) has experienced recent short-term share price momentum, prompting a valuation check. Analysts are assessing the company's financial health and market position in light of this price movement. The evaluation considers various factors, including market trends and competitive landscape, to determine the sustainability of the current share price levels. Recent share price momentum may affect investor sentiment and financial performance, but the overall impact is expected to be limited.